Showing results (81-90 of 96) with videos related to
Sort By:
Pageof 10
Behavioural Brain Research|October 16, 2025
The impact of sleep disturbance on post-transplant recovery and quality of life: Neural mechanisms and translational management strategiesPooya Vatankhah, Mohammad Nami, Mohammad Bagher Khosravi, et al.Journal of Clinical Medicine|August 23, 2020
The Interrelation of Neurological and Psychological Symptoms of COVID-19: Risks and RemediesMohammad Nami, Bharathi S Gadad, Li Chong, et al.Current Pharmaceutical Biotechnology|April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis EraAlireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.Open Journal of Immunology|November 7, 2024
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial TherapiesKenneth Blum, Igor Elman, David Han, et al.Frontiers in Public Health|December 3, 2025
Correction: Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergiaKai-Uwe Lewandrowski, Kenneth Blum, Alexander P L Lewandrowski, et al.Oxidative Medicine and Cellular Longevity|November 29, 2021
Lycopene: Food Sources, Biological Activities, and Human Health BenefitsUsman Mir Khan, Mustafa Sevindik, Ali Zarrabi, et al.Acta Scientific Neurology|September 2, 2025
Dopaminergic Homeostatic Therapy (DHT™) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS®) ScreeningKai-Uwe Lewandrowski, Abdalla Bowirrat, Albert Pinhasov, et al.Current Pharmaceutical Biotechnology|March 14, 2026
Pharmacogenomic-Based GWAS Meta-Analyses Coupled with Genetic and Epigenetic Liability Testing Connects Facial and Emotional Recognition Systems to Spectrum Disorders, Schizophrenia, Depression, and AnxietyKenneth Blum, Alexander P L Lewandrowski, Alireza Sharafshah, et al.Neurology (E-Cronicon)|December 29, 2025
Neurospirituality Connectome - Role in Neurology and Reward Deficiency Syndrome (RDS)Kenneth Blum, Eric R Braverman, Milan Makale, et al.German Medical Science : GMS E-Journal|March 23, 2017
A comprehensive approach in high-grade glioma management: position statement from the Neuro-Oncology Scientific Club (NOSC), Shiraz, IranMansour Ansari, Ahmad Mosalaei, Niloufar Ahmadloo, et al.Pageof 10